Author

Kalpesh Prajapati

Observed name: K. Prajapati

Institutions: F. Hoffmann-La Roche AG, University of California, San Francisco, Genentech, University of Basel, University Hospital of Basel, Vall d'Hebron Hospital Universitari, Centre d'Esclerosi Múltiple de Catalunya, The University of Texas Health Science Center at Houston

Observed institutions: F. Hoffmann-La Roche AG, University of California, San Francisco, Genentech, University of Basel, University Hospital of Basel, Vall d'Hebron Hospital Universitari, Centre d'Esclerosi Múltiple de Catalunya, The University of Texas Health Science Center at Houston

OpenAlex ID: A5113891272

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

2021 · Stephen L. Hauser, Ludwig Kappos, et al. · Neurology · 202

Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis

2019 · G. Giovannoni, L. Kappos, et al. · Journal of the Neurological Sciences · 5

Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis

2019 · J.S. Wolinsky, B. Brochet, et al. · Journal of the Neurological Sciences · 2

Long-Term Reduction of Relapse Rate and Confirmed Disability Progression After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

2020 · Riadh Gouider, Gavin Giovannoni, et al. · Multiple Sclerosis and Related Disorders · 1

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (1812)

2021 · Stephen L. Hauser, Ludwig Kappos, et al. · Neurology

Tolérance d’ocrelizumab (OCR) : analyse actualisée des données de tolérance des patients atteints de sclérose en plaques récurrente (SEP-R) ou primaire progressive (SEP-PP)

2021 · Stephen L. Hauser, Ludwig Kappos, et al. · Revue Neurologique

Tolérance d’ocrelizumab (OCR) : analyse actualisée des données de tolérance des patients atteints de sclérose en plaques récurrente (SEP-R) et de sclérose en plaques primaire progressive (SEP-PP)

2020 · Pierre Clavelou, Stephen L. Hauser, et al. · Revue Neurologique

Réduction à long-terme du taux de poussées et de progression du handicap après 6 ans de traitement par ocrelizumab (OCR) chez des patients atteints de sclérose en plaques récurrente (SEP-R)

2020 · Jérôme De Sèze, Gavin Giovannoni, et al. · Revue Neurologique

Works count: 8

Citation count: 210

H-index: 2

I10-index: 1